Biortus Announces Strategic Collaboration with Schrödinger

Release Time:

2024-03-01 14:34

Source:

Today, Biortus Biosciences Co. Ltd. (“Biortus”) announced a multi-year partnership with Schrodinger, whose physics-based computational platform is transforming the way therapeutics and materials are discovered, as an expansion of their ongoing collaboration to further support Schrödinger’s drug discovery programs. 


This expansion of the existing collaboration into a partnership was built upon a mutual protein-focused, structure-based approach to drug discovery. Leveraging Biortus’s gene-to-structure pipeline and capabilities, Schrödinger will be able to incorporate high-resolution structures obtained from both X-ray Crystallography and Cryo-EM into its computational platform. 

 

 

About Biortus

Biortus is a world leading independent CRO with a mature lead generation platform including modular services in soluble and membrane protein production, assay and screening, and structure determination in MicroED, CryoEM, and X-ray crystallography. Biortus now offers an off-the-shelf protein catalog to accelerate drug discovery.  


Since 2009, Biortus has partnered with numerous research institutions, biotechnology companies, and pharmaceutical companies in all fields of research around the world with sites in China and Boston, USA. To learn more about our services and capabilities, visit www.en.wuxibiortus.com (soon to be www.en.biortus.bio), follow us on LinkedIn, or subscribe to our newsletter, The Aliquot. 

Copyright © 2020 Biortus Biosciences Co.,Ltd.  Power by www.300.cn

MESSAGE

Submit
%{tishi_zhanwei}%